Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| bcl-X Protein | 3 | 2007 | 61 | 0.360 |
Why?
|
| Gossypol | 2 | 2006 | 2 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2007 | 385 | 0.320 |
Why?
|
| Neoplasm Proteins | 2 | 2007 | 360 | 0.290 |
Why?
|
| Mouth Neoplasms | 1 | 2006 | 25 | 0.280 |
Why?
|
| Laryngeal Neoplasms | 1 | 2006 | 55 | 0.270 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 87 | 0.260 |
Why?
|
| Apoptosis | 4 | 2007 | 1302 | 0.210 |
Why?
|
| Premenopause | 1 | 2021 | 26 | 0.210 |
Why?
|
| Epithelium | 1 | 2021 | 68 | 0.200 |
Why?
|
| Interleukin-10 | 1 | 2021 | 106 | 0.200 |
Why?
|
| Breast | 1 | 2021 | 92 | 0.190 |
Why?
|
| Adipose Tissue | 1 | 2021 | 208 | 0.180 |
Why?
|
| Phenotype | 1 | 2021 | 819 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2007 | 251 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2007 | 336 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2007 | 1552 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2006 | 220 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2006 | 284 | 0.080 |
Why?
|
| Sulfones | 1 | 2006 | 24 | 0.070 |
Why?
|
| Benzamides | 1 | 2006 | 54 | 0.070 |
Why?
|
| Mitotic Index | 1 | 2006 | 10 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 59 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 170 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2006 | 96 | 0.070 |
Why?
|
| Random Allocation | 1 | 2006 | 312 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2006 | 1737 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 309 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 491 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 169 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2004 | 242 | 0.060 |
Why?
|
| Hand Injuries | 1 | 2003 | 24 | 0.060 |
Why?
|
| Melanoma | 1 | 2006 | 313 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 41 | 0.050 |
Why?
|
| Telomere | 1 | 2021 | 36 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 42 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 128 | 0.050 |
Why?
|
| Adipocytes | 1 | 2021 | 128 | 0.050 |
Why?
|
| Athletic Injuries | 1 | 2003 | 226 | 0.050 |
Why?
|
| Adiposity | 1 | 2021 | 142 | 0.050 |
Why?
|
| Gene Expression | 1 | 2021 | 664 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1090 | 0.040 |
Why?
|
| Mice | 2 | 2006 | 6429 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 677 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 825 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 158 | 0.030 |
Why?
|
| Humans | 6 | 2021 | 54397 | 0.030 |
Why?
|
| Cell Survival | 2 | 2006 | 657 | 0.030 |
Why?
|
| Animals | 2 | 2006 | 14411 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 1203 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 1249 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1477 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 4319 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 50 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2006 | 22 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 73 | 0.020 |
Why?
|
| Butadienes | 1 | 2006 | 50 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 171 | 0.020 |
Why?
|
| Nitriles | 1 | 2006 | 69 | 0.020 |
Why?
|
| RNA Interference | 1 | 2006 | 195 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 133 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 13083 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2006 | 319 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 198 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 14210 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2004 | 17 | 0.020 |
Why?
|
| Dimerization | 1 | 2004 | 58 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 64 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2004 | 80 | 0.020 |
Why?
|
| Thiazoles | 1 | 2004 | 61 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2004 | 75 | 0.020 |
Why?
|
| Cisplatin | 1 | 2007 | 351 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 289 | 0.020 |
Why?
|
| Female | 2 | 2021 | 28474 | 0.010 |
Why?
|
| Foot Injuries | 1 | 2003 | 8 | 0.010 |
Why?
|
| Accidents, Home | 1 | 2003 | 9 | 0.010 |
Why?
|
| Recreation | 1 | 2003 | 21 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 92 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 684 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 386 | 0.010 |
Why?
|
| Registries | 1 | 2003 | 554 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 1097 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 1300 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 3210 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 2606 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 3830 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 4158 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 6460 | 0.010 |
Why?
|
| Child | 1 | 2003 | 7368 | 0.010 |
Why?
|
| Male | 1 | 2003 | 27348 | 0.000 |
Why?
|